Evidence map›Paper›PMID 31363959›Full record

ArticleInternational urology and nephrology2019

Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality.

Ahmed Yahia Elmowafy, Hanzada Mohamed El Maghrabi, Khaled Farouk Eldahshan, Ayman Fathi Refaie, Mohammed Adel Elbasiony, Yasser Elsayed Matter, Hazem Hamed Saleh, Gamal Elsayed Shiha, Lionel Rostaing, Mohamed Adel Bakr

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ahmed Yahia ElmowafyUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Hanzada Mohamed El MaghrabiUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Khaled Farouk EldahshanUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Ayman Fathi RefaieUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mohammed Adel ElbasionyEgyptian Liver Research Institute and Hospital, Mansoura, Egypt.
Yasser Elsayed MatterUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Hazem Hamed SalehUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Gamal Elsayed ShihaInternal Medicine Department, Mansoura University, Mansoura, Egypt.
Lionel RostaingService de Néphrologie, Dialyse, Aphérèses et Transplantation Rénale, CHU Grenoble Alpes, CS 10217, 38043, Grenoble Cedex 09, France. LRostaing@chu-grenoble.fr.ORCID http://orcid.org/0000-0002-5130-7286
Mohamed Adel BakrUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mansoura University · EGCentre Hospitalier Universitaire de Grenoble · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsNew direct-acting antiviral drugs have become the corner-stone treatment for HCV infection: they show promising results with accepted side-effects and low dropout rates. One of the available regimens is paritaprevir/ombitasvir/ritonavir (PTV/OMV/RTV). Our aim was to study the efficacy and safety of this drug regimen among HCV-positive hemodialysis patients.

methodsThis prospective single-center study was performed in the Urology and Nephrology Center, Mansoura University, Egypt. Ninety-six maintenance hemodialysis patients were screened for HCV antibodies. Positive results were found in 46 patients (47.9%). HCV PCR was assessed in all HCV-antibody-positive patients; positive results were found positive for 38 (82%); all patients were HCV genotype 4. Four patients were excluded due to advanced liver cirrhosis, liver malignancy, or metastatic breast cancer. Thirty-four patients were prescribed PTV/OMV/RTV for 3 months to treat HCV.

resultsMean age was 43.2 ± 11.9 years. Most patients were male (67.6%). There was a rapid response to treatment: HCV PCR became negative by 4 weeks after starting treatment. By 12 and 24 weeks post-DAA therapy, there was a sustained viral response (SVR 12, SVR 24) in 100% of patients with improved liver-enzyme levels.

conclusionThe PTV/OMV/RTV regimen was safe and effectively treated Egyptian HCV-positive genotype-4 hemodialysis patients.

Indexed as

Renal DialysisAdultAnilidesAntiviral AgentsCarbamatesCyclopropanesCytochrome P-450 CYP3A InhibitorsDrug CombinationsEgyptFemaleHepatitis C, ChronicHumansLactams, MacrocyclicMacrocyclic CompoundsMaleMiddle AgedAnilidesAntiviral AgentsCarbamatesCyclopropanesCytochrome P-450 CYP3A InhibitorsDrug CombinationsLactams, MacrocyclicMacrocyclic CompoundsombitasvirparitaprevirProlineRitonavirSulfonamidesValineAntiviral agentsChronic hemodialysisChronic hepatitis CDAA therapyDrug interaction

Identifiers

PMID31363959
OpenAlexW2965173872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.